专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10551300B2 Observation apparatus, observation system, data processing apparatus, and program 有权
公开(公告)号：US10551300B2
公开(公告)日：2020-02-04
申请号：US16147526
申请日：2018-09-28
申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY , NIKON CORPORATION
发明人： Yuzuru Ikehara , Josaku Sakakima
IPC分类号： G01N21/21 , G01N21/3577 , A61B5/00 , A61B5/1455 , G01N21/94
摘要： Provided is an observation apparatus that observes tissues of an organism. The observation apparatus includes a generator that generates first data obtained by irradiating the tissues with a first infrared light with a first wavelength and second data obtained by irradiating the tissues with a second infrared light with a second wavelength being different from the first infrared light in an optical property value with respect to a water, and a comparison calculator that compares the first data with the second data to generate bodily fluid data that indicates a presence of a bodily fluid on a surface of the tissues.

2. 发明申请

US20160187356A1 METHOD FOR ENRICHMENT AND SEPARATION OF SPINAL FLUID GLYCOPROTEIN, METHOD FOR SEARCHING FOR MARKER FOR CENTRAL NERVOUS SYSTEM DISEASES WHICH UTILIZES THE AFOREMENTIONED METHOD, AND MARKER FOR CENTRAL NERVOUS SYSTEM DISEASES 审中-公开
标题翻译：用于增强和分离脊髓液糖蛋白的方法，用于使用利用方法的中央神经系统疾病的标记的方法和用于中央神经系统疾病的标记的方法
公开(公告)号：US20160187356A1
公开(公告)日：2016-06-30
申请号：US15071419
申请日：2016-03-16
申请人： National Institute of Advanced Industrial Science and Technology
发明人： Hisashi Narimatsu , Jun Hirabayashi , Atsushi Kuno , Hideki Matsuzaki , Yuzuru Ikehara , Hiromi Ito , Yasuhiro Hashimoto , Keiro Shirotani , Satoshi Futakawa , Hajime Arai , Masakazu Miyajima , Kazuo Fujihara
IPC分类号： G01N33/68 , H01J49/00
CPC分类号： G01N33/6896 , G01N33/6842 , G01N2333/47 , G01N2333/4728 , G01N2400/40 , G01N2800/285 , H01J49/0036
摘要： The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
摘要翻译：本发明的目的是开发：从体液或中枢神经系统细胞中选择性分离衍生自中枢神经系统的糖蛋白的方法; 以及利用上述方法搜索中枢神经系统疾病指标的方法。可以通过两步分离方法选择性地富集来自中枢神经系统的蛋白质，其在体液或中枢神经系统细胞中发生微量的蛋白质，其包括在非还原末端除去具有唾液酸的糖蛋白从体液或中枢神经系统细胞中分离，然后在其非还原末端分离具有N-乙酰葡糖胺的糖蛋白。

3. 发明申请

US20140312241A1 PLASMA EVALUATION APPARATUS 有权
标题翻译：等离子体评估装置
公开(公告)号：US20140312241A1
公开(公告)日：2014-10-23
申请号：US14359970
申请日：2012-10-22
申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
发明人： Hajime Sakakita , Yuzuru Ikehara , Satoru Kiyama
IPC分类号： A61N5/10
CPC分类号： A61N5/1064 , A61B18/042 , A61B2017/00057 , A61B2018/00642 , A61B2018/00827 , A61B2018/00892 , H05H1/0081
摘要： [Problem] To provide a system and a method for objectively evaluating plasma by easily measuring a current generated by a plasma treatment equipment for medical purposes, etc., and a current flowing through a living body, etc.[Solution] A plasma evaluation system and method for evaluating plasma, including: a treatment target material; and a weak current measurement unit including a resistor unit and a differential amplifier, wherein the treatment target material is connected to the weak current measurement unit via a treatment target side measurement terminal, the resistor unit of the weak current measurement unit is connected to a ground side of a plasma generation current source, and the system and method evaluate plasma by receiving plasma generated by a plasma treatment equipment with the treatment target material, measuring a current by measuring a voltage across resistors of the resistor unit through the differential amplifier, and measuring an output voltage of the plasma generation power source.
摘要翻译： [问题]提供一种通过容易地测量由医疗用途等离子体处理设备等产生的电流以及流过生物体等的电流来客观评价等离子体的方法。[解决方案]等离子体评价系统和等离子体评价方法，包括：处理对象物质; 以及包括电阻单元和差分放大器的弱电流测量单元，其中所述处理对象材料经由处理对象侧测量端子连接到所述弱电测量单元，所述弱电测量单元的电阻单元连接到地等离子体产生电流源的一侧，并且该系统和方法通过接收由等离子体处理设备产生的等离子体处理设备与处理目标材料来评估等离子体，通过通过差分放大器测量电阻器单元的电阻器两端的电压来测量电流，并测量等离子体发生电源的输出电压。

4. 发明授权

US10539576B2 Lung cancer differential marker 有权
公开(公告)号：US10539576B2
公开(公告)日：2020-01-21
申请号：US15620214
申请日：2017-06-12
申请人： National Institute of Advanced Industrial Science and Technology , Tokyo Medical University
发明人： Hisashi Narimatsu , Akira Togayachi , Yuzuru Ikehara , Hiroyuki Kaji , Atsushi Kuno , Takashi Ohkura , Hideki Matsuzaki , Yoshitoshi Hirao , Jun Iwaki , Minako Abe , Masaharu Nomura , Masayuki Noguchi
IPC分类号： G01N33/574 , G01N33/68 , C07K14/47 , C07K16/28 , C07K16/30
摘要： An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.

5. 发明授权

US10408749B2 Imaging method, imaging apparatus, imaging system, surgery support system, and a storage medium 有权
公开(公告)号：US10408749B2
公开(公告)日：2019-09-10
申请号：US15922999
申请日：2018-03-16
申请人： JAPAN ORGANIZATION OF OCCUPATIONAL HEALTH AND SAFETY , NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY , NIKON CORPORATION
发明人： Kenichi Harigaya , Daisuke Ozaki , Yuzuru Ikehara , Hiroki Ishikawa , Zhen Liu , Takeshi Hataguchi
IPC分类号： G01N21/3563 , G01N33/483 , A61B5/00 , G01N21/47 , A61B5/117 , G01N21/359 , A61B10/02
摘要： An imaging method includes: irradiating breast tissue with infrared light, detecting light in a narrow wavelength band selected from wavelength bands from 1400 nm or more to 1600 nm or less, among light radiated from the tissue irradiated with the infrared light, and generating, based on the detected light in the narrow wavelength band, an image to specify an area in the tissue containing breast cancer cell aggregation or breast cancer tissue.

6. 发明授权

US10156576B2 Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases 有权
公开(公告)号：US10156576B2
公开(公告)日：2018-12-18
申请号：US15071419
申请日：2016-03-16
申请人： National Institute of Advanced Industrial Science and Technology
发明人： Hisashi Narimatsu , Jun Hirabayashi , Atsushi Kuno , Hideki Matsuzaki , Yuzuru Ikehara , Hiromi Ito , Yasuhiro Hashimoto , Keiro Shirotani , Satoshi Futakawa , Hajime Arai , Masakazu Miyajima , Kazuo Fujihara
IPC分类号： G01N33/68 , H01J49/00
摘要： The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.

7. 发明申请

US20140057286A1 Method for Measuring Glycoprotein, Method for Examining Liver Desease, Reagent for Quantitative Determination of Glycoprotein and Glycan-Marker Glycoprotein as an Index for Clinical Conditions of Liver Disease 审中-公开
标题翻译：测定糖蛋白的方法，检测肝脏酶的方法，定量测定糖蛋白和糖标记糖蛋白作为肝脏疾病临床指标的试剂
公开(公告)号：US20140057286A1
公开(公告)日：2014-02-27
申请号：US14051729
申请日：2013-10-11
申请人： Sysmex Corporation , National Center for Global Health and Medicine , Nagoya City University , National Institute of Advanced Industrial Science and Technology
发明人： Hisashi Narimatsu , Yuzuru Ikehara , Atsushi Kuno , Maki Sogabe , Yasuhito Tanaka , Masashi Mizokami , Kiyoaki Ito , Shunsuke Matsubara , Chikayuki Tsuruno , Youichi Takahama , Takashi Kagawa , Shinya Nagai
IPC分类号： G01N33/68
CPC分类号： G01N33/68 , C07K14/4726 , C07K14/473 , G01N33/5308 , G01N33/57438 , G01N33/6893 , G01N2333/4724 , G01N2333/4728 , G01N2400/00 , G01N2400/02 , G01N2800/085 , Y10T436/143333
摘要： An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.
摘要翻译：本发明的目的是提供一种测定聚糖标记糖蛋白的方法，通过该方法可以以比常规方法更高的精度检测肝脏疾病。另外，本发明的目的在于提供一种检查肝脏疾病的方法，通过该方法能够以比常规方法更高的精度检测肝脏疾病。另外，本发明的目的在于提供一种用于上述测定方法的糖蛋白定量试剂。此外，本发明的目的是提供聚糖标记糖蛋白作为肝病临床病症的指标，其能够根据肝病的进展来鉴定肝脏疾病的临床状况。测定糖蛋白的方法的特征在于：糖蛋白是从受试者收集的样品中含有的至少一种糖蛋白，其选自α-1-酸糖蛋白（AGP）和Mac-2结合蛋白（M2BP）当糖蛋白为AGP时，测量与选自AOL和MAL的第一凝集素结合的AGP; 并且当糖蛋白为M2BP时，测量与选自WFA，BPL，AAL，RCA120和TJAII的第二凝集素结合的M2BP。

8. 发明授权

US10352927B2 Glycoform detection method and glycoform detection device 有权
公开(公告)号：US10352927B2
公开(公告)日：2019-07-16
申请号：US14419804
申请日：2013-08-09
申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
发明人： Hisashi Narimatsu , Atsushi Kuno , Yuzuru Ikehara , Yasuhiro Hashimoto , Keiro Shirotani , Kiyomitsu Nara , Yoshinobu Kariya , Hiromi Ito , Kyoka Hoshi
IPC分类号： G01N33/543 , G01N33/536 , G01N33/53 , G01N33/68
摘要： It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.

9. 发明申请

US20190029090A1 LIGHT IRRADIATION SYSTEM, CONTROL APPARATUS, LIGHT IRRADIATION CONTROL METHOD, AND OPERATING MICROSCOPE APPARATUS 审中-公开
公开(公告)号：US20190029090A1
公开(公告)日：2019-01-24
申请号：US16138547
申请日：2018-09-21
申请人： National Institute of Advanced Industrial Science and Technology , Nikon Corporation
发明人： Yuzuru Ikehara , Susumu Makinouchi , Shunji Watanabe , Tetsuro Ishikawa
IPC分类号： H05B33/08 , A61B90/30 , A61B5/00 , G02B21/00 , G02F1/137 , G02F1/133 , G02B21/16 , H05B37/02
摘要： In an imaging using fluorescence, for example, it is difficult to perform a surgery while a tumor part is directly confirmed in a bright operating room. A light irradiation system according to an embodiment performs an open/close control of a first eyesight of a first eyesight restrictor and a second eyesight of a second eyesight restrictor at every predetermined time interval. The light irradiation system controls a light-on of a light such that opening and closing timings of the first eyesight match a timing of a light amount control of a surgery lamp and opening and closing timings of the second eyesight match a timing of a light amount control of a fluorescence excitation light source (see FIG. 1).

10. 发明申请

US20180106814A1 METHOD FOR MEASURING GLYCOPROTEIN, METHOD FOR EXAMINING LIVER DISEASE, REAGENT FOR QUANTITATIVE DETERMINATION OF GLYCOPROTEIN, AND GLYCAN-MARKER GLYCOPROTEIN AS AN INDEX FOR CLINICAL CONDITIONS OF LIVER DISEASE 审中-公开
公开(公告)号：US20180106814A1
公开(公告)日：2018-04-19
申请号：US15809160
申请日：2017-11-10
申请人： SYSMEX CORPORATION , NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY , NAGOYA CITY UNIVERSITY , NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
发明人： Hisashi Narimatsu , Yuzuru Ikehara , Atsushi Kuno , Maki Sogabe , Yasuhito Tanaka , Masashi Mizokami , Kiyoaki Ito , Shunsuke Matsubara , Chikayuki Tsuruno , Youichi Takahama , Takashi Kagawa , Shinya Nagai
IPC分类号： G01N33/68 , G01N33/574 , C07K14/47
CPC分类号： G01N33/68 , C07K14/4726 , C07K14/473 , G01N33/5308 , G01N33/57438 , G01N33/6893 , G01N2333/4724 , G01N2333/4728 , G01N2400/00 , G01N2400/02 , G01N2800/085 , Y10T436/143333
摘要： An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式